ACAT1 is not associated with Alzheimer's disease in two independent family-based samples SIR-Recently, a study in Molecular Psychiatry reported significant association of a noncoding single-nucleotide polymorphism (SNP) in the gene encoding acyl-Coenzyme A: cholesterol acyltransferase (ACAT1) with reduced risk for Alzheimer's disease (AD) in two small case-control samples from Central and Southern Europe. 1 The same study also described evidence linking the putative protective genotype (ie 'A/A' for SNP rs1044925) to brain amyloid load and CSF cholesterol levels. ACAT1 is a strong AD candidate gene on both biochemical and positional grounds. First, cholesterol has been implicated in the regulation of b-amyloid peptide (Ab) production, and ACAT1, which regulates the cellular levels of free cholesterol and cholesteryl esters, has been shown to reduce the Ab levels in vitro.
2 Second, the gene encoding ACAT1 (SOAT1) is located near a chromosomal region (1q25) that full genome screens suggest may harbor a novel AD gene. 3, 4 We present here the results of a comprehensive genetic assessment of SOAT1 (including all three variants previously analyzed) 1 in the NIMH AD Genetics Initiative Study sample. 4, 5 Marginally significant findings were also assessed in a smaller, independent sample of sibships discordant for AD, the 'Consortium on AD Genetics' (CAG) Study sample. 6 In contrast to the previous findings, 1 we were unable to detect any consistent evidence of genetic association with the SNPs analyzed here.
AD is a genetically complex and heterogenous disorder. To date, mutations in three genes (APP, PSEN1, PSEN2) have been established to cause early-onset autosomal dominant forms of the disease. The fourth established AD gene, encoding the brain's main cholesterol transporter apolipoprotein E (APOE) on chromosome 19q13, acts as an AD susceptibility gene. 7 While the functional basis of this risk effect has not yet been fully elucidated, it seems that APOE-e4 is involved in the accumulation and aggregation of Ab, possibly via its role in brain cholesterol metabolism. 8 Several lines of evidence suggest that numerous risk-modifying genes exist in addition to APOE. However, despite their good candidacy, none of the putatively associated cholesterol-related genes (other than APOE) has yet received more than sporadic confirmation in independent studies. This situation is quite common in AD and may be attributed to a variety of factors including small gene effects, locus and allelic heterogeneity, population admixture (in case-control studies), as well as type-I error, and publication bias. 9, 10 In an attempt to corroborate Wollmer et al's 1 findings of a protective role of SOAT1 in AD, we comprehensively examined this gene in two independent family-based AD samples (NIMH and CAG), following a multistaged approach using both haplotype and single-locus analyses. Power calculations in 'PBAT' (v1. 2) 11 based on parameters reported by Wollmer and co-workers (ie recessive mode of inheritance, disease allele frequency of B0.6, odds ratio ¼ 0.6) revealed that at a ¼ 0.05 we have approximately 80% power in the NIMH families (and nearly 90% in NIMH and CAG combined) to detect a disease locus of the previously estimated effect size. In Stage I, we tested a total of eight database SNPs (including all SNPs originally tested) 1 for their amenability to FP-SBE genotyping (for technical details see Saunders et al 12 ) , and as a preliminary assessment of linkage disequilibrium (LD) across the SOAT1 gene in 86 individuals of the NIMH sample (Table 1) . This yielded a total of four SNPs informative for followup in Stage II, which were assessed in a 'screening' subset of the NIMH sample consisting of 202 sibships discordant for AD (n ¼ 789: 440 affected, 348 unaffected; for a detailed description of the screening sample and power estimations, see Bertram et al 13 ). All four SNPs genotyped here were predicted to reside within the same haplotype block (using Haploview), 14 and visual inspection of common haplotypes (ie frequency Z0.05) revealed that these could be tagged by three variants (ie rs1543876, rs2152320, rs1044925). While association analyses using 'FBAT' (v.1.5.3; Rabinowitz and Laird 15 and Horvath et al 16 ) as previously described 13 did not show any association with the originally associated variant rs1044925, we detected nominal evidence of association with another SNP that was not previously studied (ie rs2152320; P-value ¼ 0.04 in families with 'early/ mixed' onset age using 65 years as cutoff, data not shown). This finding prompted us in Stage III to test all three haplotype tagging SNPs in the 'full' NIMH data set (which includes an additional 641 individuals in 235 additional families; for a sample description see Blacker et al 4 ), and to assess the marginally associated SNP rs2152320 in the independently collected CAG family sample, which currently includes 150 sibships (n ¼ 154 affecteds (mean age of onset 69.978.8 years, range 50-88 years), n ¼ 180 unaffecteds). 6 However, the results of these analyses did not substantiate the initially observed association with rs2152320 (Table 2) . While the extended analyses in the NIMH sample revealed a nominal (ie uncorrected for multiple comparisons) trend towards association in the 'early/mixed' onset sample (P ¼ 0.06), no evidence of association is observed in the same stratum of the CAG sample (P ¼ 0.7). Finally, none of the haplotype analyses revealed any significant signals (Table 2) .
Taken together, we have performed a comprehensive, multipronged genetic assessment of SNPs in the gene encoding ACAT1 (SOAT1) in two independent family samples, but were unable to corroborate the previously found association between this gene and AD risk. Similar discrepancies among association studies have been reported previously, both among case-control samples as well as across case-control and family-based samples. For instance, in the NIMH families we were unable to confirm a previously reported association within OLR1, 18 whereas we detected significant association with the nearby A2M gene, which was not confirmed in the majority of case-control studies. 12 Nonetheless, the familybased analyses carried out in this study are noteworthy for a number of reasons. First, unlike casecontrol studies, family-based analyses are not prone to false-positive findings due to population admixture. 17 However, given that the two case-control samples analyzed by Wollmer and co-workers show similar allele frequencies for SNP rs1044925, admixture seems unlikely in this case, particularly given that the two family samples tested in this study also show comparable allele frequencies (ie B0.4). Secondly, the strongest full-genome screen linkage results obtained in the chromosomal region near SOAT1 were actually obtained with the same NIMH families used here. 4 Thus, if the previously observed linkage signals on 1q25 were actually caused by variation in SOAT1, this should have been most obvious in the families analyzed in this report. Finally, it should be added that in addition to SOAT1, the 1q25 chromosomal region also harbors a number of other biologically compelling AD candidate genes, for example, two essential components of the g-secretase complex (nicastrin and aph-1a), which could also underlie the observed linkage signals.
In conclusion, our analyses do not support a clinically relevant contribution of genetic variants in SOAT1 on AD risk in our sample. However, these findings have no bearing on either the pathobiological Based on 86 test samples: (a) was in complete LD with rs2152318, (b) was in complete LD with rs2152320 and (c) were either not amenable to PCR amplification/FP-SBE genotyping (rs3753526) or not polymorphic (rs2256282), leading to the exclusion of these variants from further genotyping/analyses.
importance of the ACAT1 protein or the potential role of other cholesterol-related genes in AD pathogenesis. 
Note that for rs2152318 only the NIMH 'screening sample' was tested. Analyses were performed using additive as well as recessive disease models; results of both models did not differ significantly, and only the results using the additive model (which performs best in FBAT) are displayed. The average genotyping efficiency for these SNPs was 96.7%; average genotyping error rate (based on 10% blinded internal duplicates) was 0.6%. Based on build 'hg16' of the human genome sequence ('UCSC Genome Browser'; URL: http://genome.ucsc.edu/index.html), the SNPs are located at: rs1543876 (176,519,190 Mb), rs2152318 (176,532,892 Mb), rs2152320 (176,554,680 Mb) and rs1044925 (176,563,119 Mb). c Analyses in the 'total' (ie unstratified) samples. d Analyses in families with 'early-mixed' onset (ie at least one sampled affected individual showed onset prior to 65 years). Also tested but not shown were families with 'late-onset' (ie all affected individuals showed onset Z65 years), and strata based on APOE-e4 genotype; however, none of the latter analyses showed nominal P-values below 0.1.
